Hartford Investment Management Co. lowered its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 5.7% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 27,631 shares of the pharmaceutical company’s stock after selling 1,662 shares during the quarter. Hartford Investment Management Co.’s holdings in Vertex Pharmaceuticals were worth $5,083,000 as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of VRTX. Oregon Public Employees Retirement Fund grew its stake in Vertex Pharmaceuticals by 16,530.8% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 4,610,881 shares of the pharmaceutical company’s stock worth $28,000 after purchasing an additional 4,583,156 shares in the last quarter. FMR LLC lifted its holdings in Vertex Pharmaceuticals by 13.3% during the 4th quarter. FMR LLC now owns 20,483,109 shares of the pharmaceutical company’s stock worth $3,394,256,000 after buying an additional 2,411,631 shares during the last quarter. Norges Bank purchased a new stake in Vertex Pharmaceuticals during the 4th quarter worth about $380,584,000. Jennison Associates LLC lifted its holdings in Vertex Pharmaceuticals by 11.9% during the 4th quarter. Jennison Associates LLC now owns 6,941,621 shares of the pharmaceutical company’s stock worth $1,150,296,000 after buying an additional 739,128 shares during the last quarter. Finally, Thrivent Financial for Lutherans lifted its holdings in Vertex Pharmaceuticals by 74.9% during the 4th quarter. Thrivent Financial for Lutherans now owns 601,559 shares of the pharmaceutical company’s stock worth $99,685,000 after buying an additional 257,683 shares during the last quarter. Institutional investors own 94.92% of the company’s stock.
NASDAQ:VRTX traded up $3.25 during trading hours on Wednesday, reaching $172.37. 1,060,810 shares of the company traded hands, compared to its average volume of 1,383,313. The stock has a market cap of $43.22 billion, a PE ratio of 60.91, a price-to-earnings-growth ratio of 2.45 and a beta of 1.56. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.66 and a current ratio of 3.78. Vertex Pharmaceuticals Incorporated has a 1-year low of $144.07 and a 1-year high of $195.81.
Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Tuesday, April 30th. The pharmaceutical company reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.49. Vertex Pharmaceuticals had a return on equity of 22.63% and a net margin of 66.01%. The company had revenue of $857.00 million for the quarter, compared to analyst estimates of $853.00 million. During the same quarter in the prior year, the company posted $0.76 EPS. The business’s revenue for the quarter was up 34.3% compared to the same quarter last year. As a group, equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 3.06 earnings per share for the current fiscal year.
A number of analysts have issued reports on VRTX shares. BidaskClub raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, March 16th. Cowen reissued a “buy” rating and issued a $220.00 target price on shares of Vertex Pharmaceuticals in a report on Wednesday, March 6th. JPMorgan Chase & Co. reissued a “buy” rating and issued a $209.00 target price on shares of Vertex Pharmaceuticals in a report on Wednesday, May 1st. Needham & Company LLC reissued a “buy” rating and issued a $195.00 target price on shares of Vertex Pharmaceuticals in a report on Wednesday, May 1st. Finally, ValuEngine raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, May 1st. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and sixteen have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $203.62.
In other Vertex Pharmaceuticals news, EVP Stuart A. Arbuckle sold 5,624 shares of the stock in a transaction on Monday, April 15th. The stock was sold at an average price of $181.75, for a total transaction of $1,022,162.00. Following the transaction, the executive vice president now owns 36,272 shares of the company’s stock, valued at approximately $6,592,436. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Jeffrey M. Leiden sold 33,058 shares of the stock in a transaction on Monday, May 6th. The stock was sold at an average price of $175.01, for a total value of $5,785,480.58. Following the completion of the transaction, the chief executive officer now directly owns 136,953 shares in the company, valued at $23,968,144.53. The disclosure for this sale can be found here. In the last three months, insiders have sold 51,247 shares of company stock worth $8,998,147. Corporate insiders own 0.70% of the company’s stock.
Vertex Pharmaceuticals Profile
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.
Featured Story: Derivative
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.